Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA.

Mayo Clin Proc. 2008 May;83(5):584-94. doi: 10.4065/83.5.584. Review.

2.

First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.

Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.

Cochrane Database Syst Rev. 2016 May 25;(5):CD010383. doi: 10.1002/14651858.CD010383.pub2. Review.

PMID:
27223332
3.

Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.

Reck M, van Zandwijk N, Gridelli C, Baliko Z, Rischin D, Allan S, Krzakowski M, Heigener D.

J Thorac Oncol. 2010 Oct;5(10):1616-22. doi: 10.1097/JTO.0b013e3181f1c7b0.

4.

A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.

Akerley W, Boucher KM, Bentz JS, Arbogast K, Walters T.

J Thorac Oncol. 2009 Feb;4(2):214-9. doi: 10.1097/JTO.0b013e3181943bb9.

5.

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.

J Thorac Oncol. 2012 Oct;7(10):1490-502.

6.

Non-small cell lung cancer in never smokers as a representative 'non-smoking-associated lung cancer': epidemiology and clinical features.

Yano T, Haro A, Shikada Y, Maruyama R, Maehara Y.

Int J Clin Oncol. 2011 Aug;16(4):287-93. doi: 10.1007/s10147-010-0160-8. Epub 2011 May 13. Review.

PMID:
21562939
7.

Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.

Chen KY, Chen JH, Shih JY, Yang CH, Yu CJ, Yang PC.

J Thorac Oncol. 2010 Jan;5(1):82-9. doi: 10.1097/JTO.0b013e3181c09b28.

8.

Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.

Mok T, Wu YL, Au JS, Zhou C, Zhang L, Perng RP, Park K.

J Thorac Oncol. 2010 Oct;5(10):1609-15. doi: 10.1097/JTO.0b013e3181e15d55.

9.

[Lung cancer in women: clinical features and factors related to survival].

Sen E, Kaya A, Erol S, Savas I, Gonullu U.

Tuberk Toraks. 2008;56(3):266-74. Turkish.

PMID:
18932027
10.

Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.

Vinod SK, Wai E, Alexander C, Tyldesley S, Murray N.

J Thorac Oncol. 2012 Jul;7(7):1155-63. doi: 10.1097/JTO.0b013e31824fea07.

11.

[Long-term survival of personalized surgical treatment of locally advanced non-small cell lung cancer based on molecular staging].

Zhou Q, Shi Y, Chen J, Liu B, Wang Y, Zhu D, Zhang HT, Xu P, Gong Y, Chen G, Wei S, Qiu X, Niu Z, Chen X, Lei Z, Duan L, Wu Z.

Zhongguo Fei Ai Za Zhi. 2011 Feb;14(2):86-106. doi: 10.3779/j.issn.1009-3419.2011.02.15. Chinese. Erratum in: Zhongguo Fei Ai Za Zhi. 2011 Jul 20;14(7):592.

12.

Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.

Huang Y, Zhang L, Shi Y, Ma S, Liao M, Bai C, Zhang Q, Wang C, Luo F, Yu S, Qin S, Zhi X, Zhou C.

Jpn J Clin Oncol. 2015 Jun;45(6):569-75. doi: 10.1093/jjco/hyv036. Epub 2015 Apr 7.

PMID:
25855621
13.

[Epidemiology, prognostic factors, staging, and treatment of non-small cell lung cancer].

André F, Jacot W, Pujol JL, Grunenwald D, Le Chevalier T.

Bull Cancer. 1999 Oct;Suppl 3:17-41. Review. French.

PMID:
10585572
14.

From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.

Mazzoni F, Rotella V, Pratesi N, Boni L, Simi L, Orlando C, Comin CE, Maddau C, Di Costanzo F.

Tumori. 2011 Mar-Apr;97(2):160-5. doi: 10.1700/667.7777.

15.

Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R.

J Clin Oncol. 2014 Dec 1;32(34):3824-30. doi: 10.1200/JCO.2014.56.7412. Epub 2014 Oct 27.

PMID:
25349291
16.
17.

Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.

Sohn HS, Kwon JW, Shin S, Kim HS, Kim H.

J Clin Pharm Ther. 2015 Dec;40(6):661-71. doi: 10.1111/jcpt.12332. Epub 2015 Nov 17.

PMID:
26573867
18.
19.

Lung cancer in never smokers: a review.

Subramanian J, Govindan R.

J Clin Oncol. 2007 Feb 10;25(5):561-70. Review.

PMID:
17290066
20.

Lung adenocarcinoma: lessons in translation from bench to bedside.

Sangodkar J, Katz S, Melville H, Narla G.

Mt Sinai J Med. 2010 Nov-Dec;77(6):597-605. doi: 10.1002/msj.20226. Review.

PMID:
21105123

Supplemental Content

Support Center